Pharma Capital

FDA deals another blow to AstraZeneca’s ZS-9 blood drug

ZS-9 is a treatment for hyperkalaemia – a condition where potassium levels in the blood are too high
blood cells
Should it get the green light, Astra reckons ZS-9 can generate peak annual sales in excess of US$1bn

AstraZeneca PLC (LON:AZN) has suffered another setback with its ZS-9 hyperkalaemia treatment, which has been rejected for a second time by the US Food and Drug Administration.

The drug maker told investors on Friday it has received a complete response letter - a formal rejection of approval for a new drug application – from the FDA.

The pharma group said the CRL doesn’t require it to generate any new clinical which would’ve been time consuming, instead it seems that a few “matters” need ironing out.

Resolving such issues isn’t necessarily a formality though given that this was the position the company was in when its first application was knocked back last May.

The rejections cast a shadow over AstraZeneca’s US$2.7bn acquisition of ZS Pharma back in 2015, which it primarily bought to gain access to the hyperkalaemia drug.

Still, Astra has high hopes for ZS-9 – which it reckons can generate peak sales in excess of US$1bn a year – and will come back again with a revised application.

“AstraZeneca remains dedicated to developing and commercialising sodium zirconium cyclosilicate for patients with hyperkalaemia, and is confident in the profile of this potential medicine,” the company said this morning.

“AstraZeneca and ZS Pharma are committed to working with the FDA to resolve the remaining matters under review as soon as possible.”

Although ZS-9 is thought by analysts to be a ‘core’ drug in Astra’s portfolio should it get the green light, issues surrounding it will likely take back seat this year.

The real focus in the coming months is its MYSTIC lung cancer trials, which investors should hear more on later this half.

Shares were down 0.5% to £48.40.



Register here to be notified of future AZN Company articles
View full AZN profile

AstraZeneca Timeline

View All

Related Articles

picture of drug research
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.